Pluri Inc. (NASDAQ:PLUR) Short Interest Up 59.8% in December

by · The Cerbat Gem

Pluri Inc. (NASDAQ:PLUR – Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 14,548 shares, a growth of 59.8% from the December 15th total of 9,104 shares. Based on an average daily volume of 42,290 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.2% of the company’s stock are short sold. Approximately 0.2% of the company’s stock are short sold. Based on an average daily volume of 42,290 shares, the days-to-cover ratio is currently 0.3 days.

Pluri Trading Up 5.6%

Shares of Pluri stock traded up $0.17 during trading hours on Friday, reaching $3.22. 13,018 shares of the company’s stock were exchanged, compared to its average volume of 20,874. The stock has a market cap of $32.14 million, a P/E ratio of -0.68 and a beta of 0.66. The company has a 50 day moving average of $3.37 and a two-hundred day moving average of $4.27. Pluri has a fifty-two week low of $2.82 and a fifty-two week high of $7.13.

Pluri (NASDAQ:PLUR – Get Free Report) last released its earnings results on Wednesday, November 12th. The company reported ($0.65) earnings per share (EPS) for the quarter. The company had revenue of $0.32 million during the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pluri in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $12.00.

Check Out Our Latest Analysis on PLUR

Hedge Funds Weigh In On Pluri

A hedge fund recently bought a new stake in Pluri stock. Jane Street Group LLC bought a new position in shares of Pluri Inc. (NASDAQ:PLUR – Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned about 0.14% of Pluri at the end of the most recent quarter. Institutional investors own 16.59% of the company’s stock.

Pluri Company Profile

(Get Free Report)

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.

Featured Articles